医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

2023年03月08日 PM06:31
このエントリーをはてなブックマークに追加


 

TOKYO

Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230308005372/en/

Image Diagram of TAT (Graphic: Business Wire)

Image Diagram of TAT (Graphic: Business Wire)

AF will aim at establishing their pipeline (*1). Development of their radiopharmaceuticals is expected to be progressed by this funding and will lead more needs of Astatine-211. SHI is joining a new project led by Osaka University for mass production of Astatine-211 and will contribute for the development of the TAT, which is expected to be a future advanced medicine, with our technology of particle accelerators and a synthesis of radio-isotope (RI) labeled compounds.

TAT and Astatine-211

TAT is a treatment that destroys cancer cells in the human body by injecting alpha emitting RI labeled candidate which selectively targets to cancer cells. Astatine-211 (211At, Atomic number 85, Half life time 7.2H) is an element belonging to halogens and has the property of emitting alpha particle. Due to no stable isotopes in nature, their properties have not been fully elucidated so far. However, it’s getting attention in accordance with recent development of a nuclear medicine treatment and/or a theranostics (a new term combinated of therapy and diagnostic). Clinical studies had been already conducted in U.S. and Sweden etc. because of the advantages which is different from other approved RIs (177Lu, 223Ra, or 131I). The advantages are; stable production using naturally abundant bismuth (209Bi) with a relatively low-energy particle accelerator (cyclotron), short half-life time as 7.2 hours, and direct chemical formation with basic structure of candidates which conjugate with the disease target site.

In Japan, investigator-initiated clinical trials targeting differentiated thyroid cancer (jRCT2051210144) at Osaka University and pheochromocytoma paraganglioma (jRCT2021220012) at Fukushima Medical University have started and further progress is highly expected.

Alpha Fusion Inc.

AF is a startup company who is conducting a social implementation of Astatine-211 based on drug discovery transferred research results of Osaka university funded by Program on Open Innovation Platform with Enterprises, Research Institute and Achademia (OPERA) promoted by Japan Science and Technology Agency (JST). In the field of targeted alpha therapy, which has been rapidly attracting worldwide attention in recent years, Mission of the company is to let the Astatine drug development out by using its originality from Japan in the field of TAT that is rapidly attracting worldwide attention. AF aims to lead this innovative modality into the basic of cancer treatment and are aiming at the practical application of new cancer treatment by proceeding with pipeline research and development to business development on a world-class level.

Company Profile

Alpha Fusion Inc.

Head office

2-5-13, Umeda, Kita-ku, Osaka, Japan

Board of director

CEO, Sunao Fujioka

Business domain

Technical research, drug discovery development, and business development of astatine-introduced compounds into a wide range of small molecules and antibodies, including Sodium astatide

Capital

251 MJPY

Web site

https://alpha-fusion.com/

(*1) Pipelines of AF are followings. Please refer to the URL for detail.

• Pipeline 1 : Drug for thyroid cancer
(Under Phase I clinical trial : https://prtimes.jp/main/html/rd/p/000000001.000091191.html)
• Pipeline 2 : Drug for prostate cancer
(Preparing for clinical trial in next year : https://prtimes.jp/main/html/rd/p/000000003.000091191.html)
• Other 4 drugs are under development and preparing for a patent application for the basic technology

View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005372/en/

CONTACT

Sumitomo Heavy Industries, Ltd., Corporate Communication Department, +81-3-6737-2332

Alpha Fusion Inc., info@alpha-fusion.com

同じカテゴリーの記事 

  • RGA Announces 100 Billion JPY Coinsurance Transaction With Anshin Life
  • あんしん生命と1000億円の共同保険式再保険取引を発表
  • 欧州医薬品庁(EMA)、ヘンリウスとオルガノンによるProlia ® およびXgeva ® (デノスマブ)バイオシミラー候補HLX14を認証
  • 欧洲药品管理局(EMA)批准Henlius和Organon申报的Prolia ® 和Xgeva ® (地诺单抗)生物仿制药候选药物HLX14
  • European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14